Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P7Y0 | ISIN: BE0974363955 | Ticker-Symbol: 52U
Frankfurt
01.11.24
08:15 Uhr
5,560 Euro
-0,200
-3,47 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
HYLORIS PHARMACEUTICALS SA Chart 1 Jahr
5-Tage-Chart
HYLORIS PHARMACEUTICALS SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,6805,88013:04

Aktuelle News zur HYLORIS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.08.XFRA 52U: WIEDERAUFNAHME/RESUMPTION222FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
05.07.Belgian finance regulator issues warning about Hyloris Pharmaceuticals4
29.04.XFRA 52U: AUSSETZUNG/SUSPENSION293DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILHYLORIS PHARMA....
► Artikel lesen
14.03.Hyloris Pharmaceuticals SA: Hyloris Reports Full Year Results for 2023 & Provides Business Outlook444Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted to €4.4 millionStronger growth expected in 2024 of both sales and gross margin, mainly...
► Artikel lesen
14.03.Hyloris Pharmaceuticals SA: Communication at the request of the FSMA on the transactions with Qliniq254Communication at the request of the FSMA on the transactions with Qliniq Revision of 2022 and half-year of 2023 (HY 2023) financial statements following a correction of a non-cash error in the...
► Artikel lesen
27.02.Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In Canada598Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Maxigesic® IV, a Potent Non-opioid Painkiller, Marketed in the U.S. under the Tradename Combogesic® IVMaxigesic® IV approved...
► Artikel lesen
14.02.Hyloris Pharmaceuticals SA: Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures224Innovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding during and after dental procedures Approximately 280 patients...
► Artikel lesen
30.01.Hyloris Pharmaceuticals SA: Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)188Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and...
► Artikel lesen
18.01.Hyloris Pharmaceuticals SA: Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)241Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) Equal Partnership with AFT Pharmaceuticals for Development of a Drug Releasing Mucoadhesive Film for VLS (HY-091)Limited...
► Artikel lesen
16.01.Hyloris Pharmaceuticals SA: Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)199Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) PTX-252 (previously referenced as a PlecoidAgent) is a novel molecular entity developed in...
► Artikel lesen
26.12.23Hyloris Pharmaceuticals SA: Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)337Valacyclovir is an Antiviral Medication that is Commonly Used to Treat Infections Caused by Herpes Viruses Clinical Study Demonstrates Comparable Relative Bioavailability to Valaciclovir Tablets under...
► Artikel lesen
21.12.23Hyloris Pharmaceuticals SA: Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome225Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome Equal Partnership with AFT Pharmaceuticals for Development of a Novel Locally-Acting Product Candidate in Burning Mouth...
► Artikel lesen
04.12.23Hyloris Pharmaceuticals SA: Hyloris announces US FDA approval for Podofilox Gel231Hyloris announces US FDA approval for Podofilox Gel Product previously referenced as HY-016, targeting genital and perianal wartsUS Commercialization by partner Padagis to start in December 2023Second...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1